Drug Warnings: Fosamax Side Effects and Risks

Get Legal Help Today

 Secured with SHA-256 Encryption

Jeffrey Johnson is a legal writer with a focus on personal injury. He has worked on personal injury and sovereign immunity litigation in addition to experience in family, estate, and criminal law. He earned a J.D. from the University of Baltimore and has worked in legal offices and non-profits in Maryland, Texas, and North Carolina. He has also earned an MFA in screenwriting from Chapman Univer...

Full Bio →

Written by

UPDATED: Jul 16, 2021

Advertiser Disclosure

It’s all about you. We want to help you make the right legal decisions.

We strive to help you make confident insurance and legal decisions. Finding trusted and reliable insurance quotes and legal advice should be easy. This doesn’t influence our content. Our opinions are our own.

Editorial Guidelines: We are a free online resource for anyone interested in learning more about legal topics and insurance. Our goal is to be an objective, third-party resource for everything legal and insurance related. We update our site regularly, and all content is reviewed by experts.

Merck’s drug Fosamax is used to increase bone density, but recent studies have indicated that it and other bisphosphonates may also cause Osteonecrosis of the Jaw (ONJ), a condition where the tissue of the jaw bone dies and is unable to repair itself.

The FDA (Food and Drug Administration) has known for a long time that Fosamax can cause irritation of the esophagus. The FDA issued a MedWatch alert about that in 1996. In September 2004, the FDA and Novartis, the manufacturer of another bisphosphonate, issued warnings to health professionals for another more serious problem, that there is a potential for ONJ in patients treated with bisphosphonates in chemotherapy. In 2004, the FDA found 139 bisphosphonate-related ONJ cases, mostly associated with two drugs Aredia and Zometa, but 12 cases were related to Fosamax, identifying ONJ as a possible Fosamax side effect.

By October 28, 2005, 1,600 cases of bisphosphonate-related ONJ had been reported to the FDA. In January 2005, the FDA asked Merck to change the label for the drug to include a Fosamax warning about ONJ. Critics claim that the “label” in question is actually a 22-page document that is sent to pharmacies. The warning, which appears on page 13, gives no real warning to consumers.

Check out the following articles for more information about Fosamax, filing a Fosamax lawsuit and finding a Fosamax attorney.

Get Legal Help Today

Find the right lawyer for your legal issue.

 Secured with SHA-256 Encryption